CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,775,866
- in 6 filings, $831K under 10b5-1 plans
Net −$3,775,866. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Cohen Joshua B −$981K Co-Chief Executive Officer sold <1% of stake
- Klee Justin B. −$980K Co-Chief Executive Officer sold <1% of stake
- MILNE GEORGE M JR −$831K Director sold 4% of stake
- FRATES JAMES M −$350K Chief Financial Officer sold 4% of stake
- Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-05 | MILNE GEORGE M JR Director | Sale 10b5-1 | −30,000 | $27.70 | $831K | 782,881 |
| 2026-09-10 | Bedrosian Camille L Chief Medical Officer | Sale | −7,947 | $32.21 | $256K | 280,145 |
| 2026-09-10 | Bedrosian Camille L Chief Medical Officer | Sale | −2,081 | $33.09 | $69K | 278,064 |
| 2026-09-10 | FRATES JAMES M Chief Financial Officer | Sale | −9,768 | $32.27 | $315K | 234,667 |
| 2026-09-10 | FRATES JAMES M Chief Financial Officer | Sale | −1,042 | $33.23 | $35K | 233,625 |
| 2026-09-10 | Mazzariello Gina Chief Legal Officer | Sale | −9,525 | $32.46 | $309K | 190,849 |
| 2026-09-10 | Mazzariello Gina Chief Legal Officer | Sale | −11 | $33.34 | $367 | 190,838 |
| 2026-09-10 | Cohen Joshua B Co-Chief Executive Officer | Sale | −29,545 | $32.16 | $950K | 3,614,042 |
| 2026-09-10 | Cohen Joshua B Co-Chief Executive Officer | Sale | −919 | $33.15 | $30K | 3,613,123 |
| 2026-09-10 | Klee Justin B. Co-Chief Executive Officer | Sale | −29,025 | $32.13 | $933K | 3,614,495 |
| 2026-09-10 | Klee Justin B. Co-Chief Executive Officer | Sale | −1,439 | $33.16 | $48K | 3,613,056 |
| 2026-08-31 | Firestone Karen Director | Option exercise | +25,000 | $1.76 | $44K | 91,900 |
| 2026-08-31 | Firestone Karen Director | Option exercise | +25,000 | $5.05 | $126K | 116,900 |
| 2026-08-31 | Firestone Karen Director | Option exercise · Stock Option (right to buy) | −25,000 | 0 | ||
| 2026-08-31 | Firestone Karen Director | Option exercise · Stock Option (right to buy) | −25,000 | 0 | ||
| 2026-08-18 | FRATES JAMES M Chief Financial Officer | Grant or award | +22,807 | 244,435 | ||
| 2026-08-18 | Klee Justin B. Co-Chief Executive Officer | Grant or award | +60,039 | 3,643,520 | ||
| 2026-08-18 | Mazzariello Gina Chief Legal Officer | Grant or award | +21,284 | 200,374 | ||
| 2026-08-18 | Bedrosian Camille L Chief Medical Officer | Grant or award | +22,807 | 288,092 | ||
| 2026-08-18 | Cohen Joshua B Co-Chief Executive Officer | Grant or award | +60,039 | 3,643,587 |
Page 1 of 18 · 350 trades